AACR Recognizes World Cancer Day on February 4
PHILADELPHIA – The American Association for Cancer Research (AACR) today joins individuals and organizations around the world in recognizing...
Search/Filter
Loading...
AACR Statement on the New Administration’s Recent Executive Orders and Policy Proposals
The American Association for Cancer Research (AACR) is increasingly concerned about the numerous executive orders and policy proposals that...
A Therapeutic HPV Vaccine Could Eliminate Precancerous Cervical Lesions
PHILADELPHIA – A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according...
AACR Expresses Sincere Appreciation to NIH Director Monica M. Bertagnolli, MD
PHILADELPHIA — The American Association for Cancer Research (AACR) today expressed its gratitude to Monica M. Bertagnolli, MD, for...
ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence
The study was terminated early due to low detection of ctDNA after treatment among patients with stage 1 to...
HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From Addition of Anthracyclines to Taxane- based Chemotherapy
Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of...
Multimodal Machine Learning Model Effective at Predicting Response to CDK4/6 Inhibitors in HR-positive, HER2-negative Breast Cancer Patients
Combining real-world clinical and genomic data resulted in a more accurate prediction of outcomes compared to examining clinical and...
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients with ‘Good-risk’ DCIS Who Forgo Radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not...
Most Patients With Intermediate-risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy
SAN ANTONIO – Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they...
COMET Trial Finds Active Monitoring Is a Viable Option for Some Patients With Low-risk DCIS
Recurrence risk was similar between active monitoring and usual care groups SAN ANTONIO – Among patients with hormone receptor...